Effects of combined phytochemicals on skin tumorigenesis in SENCAR mice

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 911-918

  Kowalczyk, Magdalena C ^a   Junco, Jacob J ^a   Kowalczyk, Piotr ^a   Tolstykh, Olga ^a   Hanausek, Margaret ^a,b   Slaga, Thomas J ^a,b,c   Walaszek, Zbigniew ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Carcinogenesis; Phytochemicals; Prevention; SENCAR mice; Skin

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CALCIUM D GLUCARATE; CYCLOOXYGENASE 2; INTERLEUKIN 6; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN C JUN; PROTEIN P50; RESVERATROL; SACCHARIC ACID; UNCLASSIFIED DRUG; URSOLIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS HYPERPLASIA; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKIN CARCINOGENESIS; SKIN TUMOR; TUMOR PROMOTION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCARIC ACID; HUMANS; INTERLEUKIN-6; MICE; MICE, INBRED SENCAR; PHYTOCHEMICALS; SKIN NEOPLASMS; STILBENES; TETRADECANOYLPHORBOL ACETATE; TRITERPENES;

EID: 84880589938     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2005     Document Type: Article

References (49)

1. Bishop JM: Molecular themes in oncogenesis. Cell 64: 235-248, 1991.
2. Knudson AG: Hereditary predisposition to cancer. Ann NY Acad Sci 833: 58-67, 1997.
3. Boutwell RK: Some biological aspects of skin carcinogenisis. Prog Exp Tumor Res 4: 207-250, 1964.
4. Slaga TJ: Cancer: etiology, mechanisms, and prevention - a summary. Carcinog Compr Surv 5: 243-262, 1980.
5. DiGiovanni J: Multistage carcinogenesis in mouse skin. Pharmacol Ther 54: 63-128, 1992.
6. Kemp CJ: Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol 15: 460-473, 2005.
7. Perez-Losada J and Balmain A: Stem-cell hierarchy in skin cancer. Nat Rev Cancer 3: 434-443, 2003.
8. Hanausek M, Ganesh P, Walaszek Z, Arntzen CJ, Slaga TJ and Gutterman JU: Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model. Proc Natl Acad Sci USA 98: 11551-11556, 2001.
9. Kim EJ, Park H, Kim J and Park JH: 3,3'-diindolylmethane suppresses 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and tumor promotion in mouse skin via the downregulation of inflammatory mediators. Mol Carcinog 49: 672-683, 2010.
10. Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ and Jorcano JL: Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 18: 7423-7431, 1999.
11. Przybyszewski J, Yaktine AL, Duysen E, et al: Inhibition of phorbol ester-induced AP-1-DNA binding, c-Jun protein and c-jun mRNA by dietary energy restriction is reversed by adrenalectomy in SENCAR mouse epidermis. Carcinogenesis 22: 1421-1427, 2001.
12. Walaszek Z, Hanausek M and Slaga TJ: Mechanisms of chemoprevention. Chest 125: S128-S133, 2004.
13. Taesotikul T, Dumrongsakulchai W, Wattanachai N, Navinpipat V, Somanabandhu A and Tassaneeyakul W: Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metab Pharmacokinet 26: 154-161, 2011.
14. Kimura Y, Ito H, Ohnishi R and Hatano T: Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 48: 429-435, 2010.
15. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E and Fujiki H: Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59: 44-47, 1999.
16. Saw CL, Cintron M, Wu TY, et al: Pharmacodynamics of dietary phytochemical indoles I3C and DIM: induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm Drug Dispos 32: 289-300, 2011.
17. Khafif A, Schantz SP, Chou TC, Edelstein D and Sacks PG: Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19: 419-424, 1998.
18. Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P and Marambaud P: Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci 9 (Suppl 2): S6, 2008.
19. Bishayee A: Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2: 409-418, 2009.
20. Das M and Das DK: Resveratrol and cardiovascular health. Mol Aspects Med 31: 503-512, 2010.
21. Brasnyo P, Molnar GA, Mohas M, et al: Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106: 383-389, 2011.
22. Howells LM, Berry DP, Elliott PJ, et al: Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res 4: 1419-1425, 2011.
23. Patel KR, Brown VA, Jones DJ, et al: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392-7399, 2010.
24. Walaszek Z, Szemraj J, Narog M, et al: Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. Cancer Detect Prev 21: 178-190, 1997.
25. Yoshimi N, Walaszek Z, Mori H, Hanausek M, Szemraj J and Slaga TJ: Inhibition of azoxymethane-induced rat colon carcinogenesis by potassium hydrogen D-glucarate. Int J Oncol 16: 43-48, 2000.
26. Hanausek M, Walaszek Z and Slaga TJ: Detoxifying cancer causing agents to prevent cancer. Integr Cancer Ther 2: 139-144, 2003.
27. Abou-Issa H, Moeschberger M, el-Masry W, Tejwani S, Curley RW Jr and Webb TE: Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res 15: 805-810, 1995.
28. Huang MT, Ho CT, Wang ZY, et al: Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res 54: 701-708, 1994.
29. De Angel RE, Smith SM, Glickman RD, Perkins SN and Hursting SD: Antitumor effects of ursolic acid in a mouse model of postmenopausal breast cancer. Nutr Cancer 62: 1074-1086, 2010.
30. Shan JZ, Xuan YY, Zheng S, Dong Q and Zhang SZ: Ursolic acid inhibits proliferation and induces apoptosis of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway. J Zhejiang Univ Sci B 10: 668-674, 2009.
31. Kassi E, Papoutsi Z, Pratsinis H, Aligiannis N, Manoussakis M and Moutsatsou P: Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells. J Cancer Res Clin Oncol 133: 493-500, 2007.
32. Kassi E, Sourlingas TG, Spiliotaki M, et al: Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells. Cancer Invest 27: 723-733, 2009.
33. Fischer SM, Pavone A, Mikulec C, Langenbach R and Rundhaug JE: Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog 46: 363-371, 2007.
34. Lederle W, Depner S, Schnur S, et al: IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int J Cancer 128: 2803-2814, 2011.
35. Ullevig SL, Zhao Q, Zamora D and Asmis R: Ursolic acid protects diabetic mice against monocyte dysfunction and accelerated atherosclerosis. Atherosclerosis 219: 409-416, 2011.
36. Young MR, Li JJ, Rincon M, et al: Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA 96: 9827-9832, 1999.
37. Thompson EJ, MacGowan J, Young MR, Colburn N and Bowden GT: A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. Cancer Res 62: 3044-3047, 2002.
38. Kowalczyk MC, Walaszek Z, Kowalczyk P, Kinjo T, Hanausek M and Slaga TJ: Differential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: implications for skin cancer prevention. Carcinogenesis 30: 1008-1015, 2009.
39. Shahin V, Ludwig Y, Schafer C, Nikova D and Oberleithner H: Glucocorticoids remodel nuclear envelope structure and permeability. J Cell Sci 118: 2881-2889, 2005.
40. Thompson S and Slaga TJ: The effects of dexamethasone on mouse skin initiation and aryl hydrocarbon hydroxylase. Eur J Cancer 12: 363-370, 1976.
41. Baynes RE, Halling KB and Riviere JE: The influence of diethyl-m-toluamide (DEET) on the percutaneous absorption of permethrin and carbaryl. Toxicol Appl Pharmacol 144: 332-339, 1997.
42. Baynes RE, Brownie C, Freeman H and Riviere JE: In vitro percutaneous absorption of benzidine in complex mechanistically defined chemical mixtures. Toxicol Appl Pharmacol 141: 497-506, 1996.
43. Williams AC and Barry BW: Penetration enhancers. Adv Drug Deliv Rev 56: 603-618, 2004.
44. Banerjee S, Bueso-Ramos C and Aggarwal BB: Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62: 4945-4954, 2002.
45. Cui X, Jin Y, Hofseth AB, et al: Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res 3: 549-559, 2010.
46. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA and Lamartiniere CA: Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28: 1946-1953, 2007.
47. George J, Singh M, Srivastava AK, et al: Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One 6: e23395, 2011.
48. Kapadia GJ, Azuine MA, Tokuda H, et al: Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis. Pharmacol Res 45: 499-505, 2002.
49. Kowalczyk MC, Kowalczyk P, Tolstykh O, Hanausek M, Walaszek Z and Slaga TJ: Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev Res 3: 170-178, 2010.